Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025
Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025
Xilio Therapeutics的第一季度现金和现金等价物为3,400万美元，根据吉利德协议于2024年4月收到的3000万美元预付款，以及2024年4月的私募总收益约为1460万美元，预计将为2025年第二季度提供现金流道
Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025
Xilio Therapeutics的第一季度现金和现金等价物为3,400万美元，根据吉利德协议于2024年4月收到的3000万美元预付款，以及2024年4月的私募总收益约为1460万美元，预计将为2025年第二季度提供现金流道
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。